Skip to main content

Table 2 Clinicopathologic characteristics of patients for entire series and from first (1999–2008) and second (2009–2018) period

From: Primary localized retroperitoneal sarcomas: report from Slovenian sarcoma referral center

Characteristic

All patients, n = 89

First period, n = 41

Second period, n = 48

p

Gender

   

0.833

 Male

47 (52.8%)

21 (51.2%)

26 (54.2%)

 

 Female

42 (47.2%)

20 (48.8%)

22 (45.8%)

 

Age, median (years)

62 (range 24–84)

64 (range 31–82)

62 (range 24–84)

0.922

ASA score

   

0.108

 1

17 (19.1%)

11 (26.8%)

6 (12.5%)

 

 2

43 (48.3%)

17 (41.5%)

26 (54.2%)

 

 3

22 (24.7%)

9 (22.0%)

13 (27.1%)

 

 4

4 (4.5%)

1 (2.4%)

3 (6.3%)

 

 Unknown

3 (3.4%)

3 (7.3%)

0

 

Histologic subtype

   

0.424

 Dedifferentiated liposarcoma

34 (38.2%)

14 (34.1%)

20 (41.7%)

 

 Well-differentiated liposarcoma

19 (21.3%)

12 (29.3%)

7 (14.6%)

 

 Leiomyosarcoma

14 (15.7%)

7 (17.1%)

7 (14.6%)

 

 Solitary fibrous tumor

8 (9.0%)

3 (7.3%)

5 (10.4%)

 

 Malignant peripheral nerve sheath tumor

2 (2.2%)

0

2 (4.2%)

 

 Other

12 (13.5%)

5 (12.2%)

7 (14.6%)

 

FNCLCC Grade

   

0.054

 I

31 (34.8%)

21 (51.2%)

10 (20.8%)

 

 II

16 (18.0%)

5 (12.2%)

11 (22.9%)

 

 III

30 (33.7%)

13 (31.7%)

17 (35.4%)

 

 Unknown

12 (13.5%)

2 (4.9%)

10 (20.8%)

 

Median tumor size (cm)

21 (range 3–80)

24 (range 7–80)

19.5 (range 3–58)

0.403

Radiotherapy

    

 Neoadjuvant

4 (4.5%)

0

4 (8.3%)

0.059

 Adjuvant

7 (7.9%)

5 (12.2%)

2 (4.2%)

0.241

Chemotherapy

    

 Neoadjuvant

2 (2.2%)

1 (2.4%)

1 (2.1%)

1.0

 Adjuvant

2 (2.2%)

2 (4.9%)

0

0.209

Surgical resection margin

   

0.044

 R0

68 (76.4%)

27 (65.9%)

41 (85.4%)

 

 R1

21 (23.6%)

14 (34.1%)

7 (14.6%)

 

 R2

0

0

0

 

Median time to treatment (days)

27.0 (range 0–181)

16.0 (range 0–65)

35.0 (range 4–181)

< 0.001

Median weight of the specimen (g)

2259 (range 12–32,600)

3450 (range 86–32,600)

2006 (range 12–13,000)

0.087

Stage (AJCC 8th edition)

   

0.166

 1A

1 (1.1%)

0

1 (2.1%)

 

 1B

42 (47.2%)

23 (56.1%)

19 (39.6%)

 

 3A

7 (7.9%)

1 (2.4%)

6 (12.5%)

 

 3B

39 (43.8%)

17 (41.5%)

22 (45.8%)

 

Median surgery duration (hours)

7.3 (range 1.3–19.0)

7.5 (range 2–14.5)

7.0 (range 1.3–19)

0.669

Median blood loss (l)

1.0 (range minimal–32)

0.8 (range minimal–32)

1.4 (range minimal–30)

0.853

Resection type

   

0.266

 Tumorectomy

2 (2.2%)

0

2 (2.2%)

 

 Tumor removed with at least one organ, but not compartmental resection

45 (50.6%)

19 (21.3%)

26 (29.2%)

 

 Compartmental resection

42 (47.2%)

22 (24.7%)

20 (22.5%)

 

Complication rate

   

0.214

 Clavien-Dindo 3a

7 (7.9%)

4 (9.8%)

3 (6.3%)

 

 Clavien-Dindo 3b

9 (10.1%)

5 (12.2%)

4 (8.3%)

 

 Clavien-Dindo 4a

3 (3.4%)

1 (2.4%)

2 (4.2%)

 

 Clavien-Dindo 4b

3 (3.4%)

0

3 (6.3%)

 

 Clavien-Dindo 5 (90 days)

5 (5.6%)

0

5 (10.4%)

 

Median hospital stay after surgery (days)

22.0 (range 2–102)

23.0 (range 10–77)

21.0 (range 2–102)

0.952

Median ICU stay (days)

8.0 (range 0–55)

9.0 (range 4–22)

7.5 (range 0–55)

0.939

  1. ASA American Society of Anesthesiologists classification, FNCLCC Fédération Nationale des Centres de Lutte Contre Le Cancer, AJCC American Joint Committee on Cancer, ICU intensive care unit